JP2013536206A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536206A5
JP2013536206A5 JP2013525143A JP2013525143A JP2013536206A5 JP 2013536206 A5 JP2013536206 A5 JP 2013536206A5 JP 2013525143 A JP2013525143 A JP 2013525143A JP 2013525143 A JP2013525143 A JP 2013525143A JP 2013536206 A5 JP2013536206 A5 JP 2013536206A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutically acceptable
phenyl
dimethyl
phenylsulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013525143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536206A (ja
JP5902169B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2011/050317 external-priority patent/WO2012025123A1/en
Publication of JP2013536206A publication Critical patent/JP2013536206A/ja
Publication of JP2013536206A5 publication Critical patent/JP2013536206A5/ja
Application granted granted Critical
Publication of JP5902169B2 publication Critical patent/JP5902169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013525143A 2010-08-23 2011-08-22 1−[2−(2,4−ジメチル−フェニルスルファニル)フェニル]ピペラジンの治療的使用 Active JP5902169B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
US61/375,885 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (3)

Publication Number Publication Date
JP2013536206A JP2013536206A (ja) 2013-09-19
JP2013536206A5 true JP2013536206A5 (enExample) 2014-10-09
JP5902169B2 JP5902169B2 (ja) 2016-04-13

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013525143A Active JP5902169B2 (ja) 2010-08-23 2011-08-22 1−[2−(2,4−ジメチル−フェニルスルファニル)フェニル]ピペラジンの治療的使用

Country Status (32)

Country Link
US (5) US20130184291A1 (enExample)
EP (1) EP2608789B2 (enExample)
JP (1) JP5902169B2 (enExample)
KR (1) KR101816953B1 (enExample)
CN (1) CN103068389A (enExample)
AP (1) AP3583A (enExample)
AR (1) AR082501A1 (enExample)
AU (1) AU2011295465B8 (enExample)
BR (2) BR112013002194A2 (enExample)
CA (1) CA2807062C (enExample)
CL (1) CL2013000492A1 (enExample)
CO (1) CO6680652A2 (enExample)
CY (1) CY1118886T1 (enExample)
DK (1) DK2608789T4 (enExample)
ES (1) ES2625142T5 (enExample)
FI (1) FI2608789T4 (enExample)
HR (1) HRP20170608T4 (enExample)
HU (1) HUE034155T2 (enExample)
IL (1) IL224371A (enExample)
LT (1) LT2608789T (enExample)
ME (1) ME02674B (enExample)
MX (1) MX349724B (enExample)
PL (1) PL2608789T5 (enExample)
PT (1) PT2608789T (enExample)
RS (1) RS55851B2 (enExample)
RU (1) RU2564666C2 (enExample)
SG (1) SG187649A1 (enExample)
SI (1) SI2608789T2 (enExample)
SM (1) SMT201700239T1 (enExample)
TW (1) TW201212918A (enExample)
WO (1) WO2012025123A1 (enExample)
ZA (1) ZA201301385B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DK0543584T3 (da) * 1991-11-18 1996-07-01 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamider til behandling af forstyrrelser i centralnervesystemet
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7159383B2 (en) 2000-10-02 2007-01-09 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
BR122020011920A2 (pt) 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Similar Documents

Publication Publication Date Title
TWI776407B (zh) 激動劑形成之調配物及使用其之方法
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP2024074963A (ja) トラジピタントによる治療方法
JP2014517050A5 (enExample)
JP2017528507A5 (enExample)
JP2013536206A5 (enExample)
CN111902417A (zh) 一种二芳基巨环化合物、药物组合物以及其用途
CA3083341C (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JP2024016113A (ja) ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
JP2019507786A5 (enExample)
US9724340B2 (en) Antitussive compositions and methods
JP2021504384A5 (enExample)
CN110573148A (zh) 特发性肺纤维化的治疗
Grunberg et al. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management: Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
JP2012502105A5 (enExample)
JP2007519646A (ja) 体重の持続的低減のための化合物
JP2021503448A5 (enExample)
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
TWI864376B (zh) 焦慮症處置用組成物及處置方法
JP6734469B2 (ja) ヒスタミン−3受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びnmda受容体アンタゴニストの3種組合せ
WO2016006621A1 (ja) Pgd2拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
JP2015515971A5 (enExample)
US20240358693A1 (en) Methods of treating pain